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ABSTRACT  
Objective: The main objective of this study was to evaluate the ability of sodium phenylbutyrate (NaPB) to enhance the cytotoxicity of 5-
fluorouracil, oxaliplatin, and irinotecan against colorectal cancer cell lines expressing wild-type and mutant p53.  
Methods: The antiproliferative effect of NaPB alone or in combination with 5-fluorouracil, oxaliplatin, or irinotecan in HCT-116 and HT-29 
colorectal cancer cell lines was investigated using the MTT cell proliferation assay. IC50 values were calculated using Compusyn Software 1.0 
(Combosyn Inc.). Synergy values (R) were calculated using the ratio of IC50 of each primary drug alone divided by combination IC50
Results: NaPB inhibited the growth of HCT-116 and HT-29 cell lines in a dose-dependent manner (IC
s. For each two 
pairs of experiments, student’s t-test was used for analysis. In combination studies, one-way ANOVA test; Tukey post-hoc testing was performed 
using R 3.3.2 software. P-value<0.05 was considered significant. 
50
Conclusion: NaPB enhanced the cytotoxicity of conventional chemotherapy against colorectal cancer cell lines harboring wild-type or mutant p53. 
Thus NaPB is a promising potential adjuvant chemotherapy in colorectal cancer. 
s 4.7 mmol, and 10.1 mmol, respectively). 
HT-29 cell lines (mutant p53) were more sensitive to NaPB at low concentrations (<4 mmol). Moreover, the addition of NaPB to HCT-116 and HT-29 
with 5-fluorouracil, oxaliplatin, or irinotecan synergistically induced the antiproliferative effect (R>1.6, p-value<0.05).  
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Colorectal cancer is the third most common cancer in both sexes and 
it is among the most common causes of cancer-related deaths in the 
United States [1]. In Jordan, colorectal cancer accounts for 10.3% 
and 8.9% of cancer-related deaths in males and females, respectively 
[2]. Surgical resection of the primary tumor and involved lymph 
nodes is the primary treatment for early-stage localized tumors. 
However, for advanced-stage metastatic tumors, adjuvant 
chemotherapy is the mainstay of therapy [3]. About 55% of 
colorectal cancer patients present with advanced stages at the time 
of diagnosis, and half of the patients who undergo surgery ultimately 
develop a metastatic disease [4-6]. Adjuvant chemotherapy 
consisting mainly of 5-fluorouracil, oxaliplatin, and irinotecan, has 
been associated with improved response rates, reduced risk of 
tumor recurrence and mortality, and enhanced disease-free and 
median survival rates [4-8]. Despite the advances in chemotherapy 
and targeted molecular agents, about 90% of patients with advanced 
metastatic colorectal cancer fail therapy, which is mainly attributed 
to resistance, either intrinsic or acquired [9, 10].  
The high resistance and toxicity profile associated with the current 
chemotherapeutic agents highlight the urgent need for the 
identification of new adjuvant therapies. Such agents will act 
synergistically to sensitize tumor cells to the currently approved 
anticancer drugs, overcome therapy resistance, and reduce dose 
requirements and thus the drug-induced adverse effects. Taking 
advantage of potential antineoplastic agents that are currently 
approved and used for the treatment of disease conditions other 
than cancer is highly encouraged to evade the costly and exacting 
processes of development of novel anticancer agents. Agents 
targeting epigenetic mechanisms are among the future promising 
therapies for enhancing the response of the currently approved 
anticancer drugs. The proof-of-concept for that is the approval of 
histone deacetylase (HDAC) inhibitors (HDACIs); vorinostat, 
romidepsin, panobinostat, and belinostat by the US Food and Drug 
Administration for use in haematological cancers [11, 12]. 
HDACIs showed anticancer effects through the inhibition of tumour 
cell growth and induction of cellular apoptosis and differentiation in 
malignant cells [13]. Their recruitment in the anticancer regimen 
enhanced the cytotoxicity of several anticancer agents [14, 15]. 
Sodium phenylbutyrate (NaPB), the salt of a short-chain fatty acid, is 
a HDACI and was the first of its class to be encountered [16, 17]. 
Numerous studies have revealed the antineoplastic potential of this 
agent in different types of cancers, including colorectal cancer, in 
vitro and in vivo [18-21].  
In this study, we were prompted to investigate the ability of NaPB to 
sensitize the colorectal cancer cell lines to 5-fluorouracil, oxaliplatin, 
and irinotecan and overcome the resistance against these agents.  
MATERIALS AND METHODS 
Drugs 
Irinotecan was purchased from Sigma-Aldrich (St. Louis, MO, USA) 
and dissolved in dimethyl sulfoxide (DMSO) at a concentration of 
160 mmol, and 5-fluorouracil and oxaliplatin were purchased from 
Combi-Blocks (San Diego, CA, USA) and dissolved in DMSO at 
concentrations of 385 mmol and 378 mmol, respectively. NaPB was 
obtained from Combi-Blocks (San Diego, CA, USA) and dissolved in 
nuclease-free water at a concentration of 2 M. All drugs were stored 
in dark-coloured bottles at-20 °C as stock solutions.  
Cell culture and drug treatment 
HCT-116 and HT-29 human colorectal cancer cell lines were 
purchased from the American Type Culture Collection (ATCC, 
Manassas, VA, USA). Both cell lines were cultured in Dulbecco’s 
modified Eagle’s medium (DMEM, Euroclone, Italy) supplemented 
with 10% fetal bovine serum (Euroclone, Italy) and 1 % penicillin/ 
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streptomycin (100 IU/ml penicillin and 100 µg/ml streptomycin, 
Euroclone, Italy). Both cell lines were maintained in a humidified 
incubator of 95% air and 5% CO2 atmosphere at 37 °C. Drug stocks 
were diluted to the required concentrations with culture media 
immediately before use. Before treatment with the drugs, the medium 
was removed when cells were adherent and about 80 % confluent.  
MTT assay 
The cells were plated in 96 well plates at a density of 5 x 103 in 200 µl of 
medium per well and the cells were incubated and allowed to attach 
overnight. The attached cells in the plates were treated with a series of 
drug concentrations; NaPB (0-32 mmol), or 5-fluorouracil (0-200 µM), 
oxaliplatin (0-300 µM), or irinotecan (0-160 µM) alone or in combination 
with three different concentrations of NaPB (IC50, 0.5X IC50, 2X IC50). 
Cells grown in medium alone (for treatment with NaPB only) or 
containing an equivalent amount of DMSO served as control (for other 
treatment conditions). Cells were incubated with the drugs at the 
indicated concentrations for 72 h. All measurements were done in 
triplicate. After that, the cell proliferation assay was performed per 
manufacturer’s protocol. Briefly, MTT dye was added to the treated cells 
at a final concentration of 0.5 mg/ml in PBS. After that the plates were 
incubated at 37 °C for 3 h, then the MTT was discarded and the formazan 
product was dissolved by adding 100 µl of DMSO to each well, followed 
by shaking for 5 min. Then the plates were read using an enzyme-linked 
immunosorbent assay (ELISA) plate reader at 570 nm with a reference 
wavelength of 690 nm. Cells viability was calculated as follows: 
Absorbance of the experimental group/absorbance of the control group. 
The IC50 value was defined as the concentration needed for a 50% 
reduction in cell viability. Dose-effect analyses and IC50
Analysis of the effects of drug combinations 
 calculations were 
performed using Compusyn Software 1.0 (Combosyn Inc.).  
The effects of different drug combinations were determined as 
previously described by Richard et al. [22]. Synergy values (R) were 
calculated using the ratio of IC50 of each primary drug alone (5-
fluorouracil, oxaliplatin, or irinotecan) divided by combination IC50
Statistical analysis 
s. 
R-value reflects the extent of synergism or antagonism for two 
drugs: R>1.6, synergism; R=1, additive effect; R<1, antagonism.  
All results were expressed as the mean±standard deviation. For each 
two pairs of experiments, student’s t-test was used for analysis. For 
comparison of IC50 values of monotherapy versus combination IC50
RESULTS  
, 
student’s t-test was performed. For analysis of the results of 
combination studies, One-way ANOVA test; Tukey post-hoc testing 
was performed using R 3.3.2 Software. Statistical significance was 
considered if p-value<0.05.  
NaPB inhibited the growth of colorectal cancer cell lines 
We utilized two different colorectal cancer cell lines; HCT-116 and HT-
29. Initially, we investigated the effects of NaPB on the proliferation of 
the two cell lines, using the MTT assay performed after 72 h of 
treatment. As shown in fig. 1, NaPB exerted antiproliferative effects in 
a dose-dependent manner against the two cell lines. 
 
Fig. 1: Antiproliferative effect of NaPB on HCT-116 and HT-29 
colorectal cancer cell lines, NaPB concentrations were ranging 
from 0.5-32 mmol. Attached cells were treated and maintained 
in the drug-containing medium for 72 h before being analyzed 
by MTT. Triplicate experiments were performed. Data are 
expressed as mean±standard deviation. NaPB inhibited the 
growth of HCT-116 and HT-29 cell lines in a dose-dependent 
manner. Student’s t-test was used for analysis and statistical 
significance was considered if p<0.05 
 
The IC50 values were about 5 mmol and 10 mmol in HCT-116 and 
HT-29, respectively (table 1). 
 
Table 1: Inhibitory concentrations of 50% viability (IC50
Colorectal cancer cell lines 
s) for 
NaPB and chemotherapy drugs in HCT-116 and HT-29 
HCT-116 HT-29 
NaPB (mM) 4.7 10.1 
5-fluorouracil (µM) 2.9 200 
Oxaliplatin (µM) 9.8 9.8 
Irinotecan (µM) 0.4 1.7 
 
Synergistic growth inhibition by NaPB in combination with 5-
fluorouracil, oxaliplatin, and irinotecan 
For the combined treatment, the two colorectal cancer cell lines 
were treated with varying concentrations of 5-fluorouracil (0-200 
µM), oxaliplatin (0-300 µM), or irinotecan (0-160 µM) in the 
presence or absence of three different concentrations of NaPB that 
corresponded to 0.5X IC50, IC50, and 2X IC50
 
 (2.5, 5, and 10 mmol in 
HCT-116; and 5, 10, and 20 mmol in HT-29). The growth inhibitory 
effect was measured in the two cell lines by MTT assays. As shown in 
fig. 2, our results revealed that at clinically achievable and non-toxic 
concentrations, NaPB enhanced the antiproliferative effect of the 
three tested anticancer agents in a dose-dependent manner. 
Table 2: Combination IC50s*
HCT-116 
 and synergy values (R) in HCT-116 and HT-29 colorectal cancer cell lines 
IC p-value 50 R HT-29 IC p-value 50 R 
5-fluorouracil    5-fluorouracil    
 Plus 2.5 mmol NaPB 0.2 0.006 14.5  Plus 5 mmol NaPB 36 0.000 5.6 
Plus 5 mmol NaPB 6.60E-10 0.029 4.39E+09 Plus 10 mmol NaPB 1.6 0.000 125 
 Plus 10 mmol NaPB 4.01E-07 0.026 7.23E+06  Plus 20 mmol NaPB 3.40E-10 0.000 5.87E+11 
Oxaliplatin    Oxaliplatin    
 Plus 2.5 mmol NaPB 1.7 0.022 5.8  Plus 5 mmol NaPB 1.3 0.004 7.8 
Plus 5 mmol NaPB 0.96 0.019 10.2 Plus 10 mmol NaPB 0.8 0.002 12.9 
 Plus 10 mmol NaPB 0.0007 0.002 14000  Plus 20 mmol NaPB 9.40E-08 0.006 1.04E+08 
Irinotecan    Irinotecan    
 Plus 2.5 mmol NaPB 0.0075 0.011 53.39  Plus 5 mmol NaPB 0.3 0.017 5.7 
Plus 5 mmol NaPB 1.49E-38 0.008 2.69E+37 Plus 10 mmol NaPB 0.08 0.019 21.3 
 Plus 10 mmol NaPB 1.11E-55 0.008 3.59E+54  Plus 20 mmol NaPB 8.70E-06 0.019 1.95E+05 
*IC50: inhibitory concentration of 50% viability, **IC50 values of monotherapy and combination were compared using the student’s t-test, ***R: synergy value 
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Fig. 2: Effect of treatment with 5-fluorouracil, oxaliplatin, and irinotecan, alone or combined with NaPB on cell proliferation of HCT-116 
(A1-A3), and HT-29 (B1-B3) colorectal cancer cell lines, Cell viability was assessed using MTT assay. Cell viability was measured after 
treatment with a series of drugs’ concentrations; 5-fluorouracil (0-200 µM) [A1 and B1], oxaliplatin (0-300 µM) [A2 and B2], or irinotecan 
(0-160 µM) [A3 and B3] alone or combined with three different concentrations of NaPB (0.5X IC50, IC50, 2X IC50
 
) for 72 h. Cells grown in 
medium containing an equivalent amount of DMSO served as control. Each treatment condition was performed in triplicate. Data are 
expressed as mean±standard deviation. One-way ANOVA test; Tukey post-hoc was used for analysis and statistical significance was 
considered if p-value<0.05 
After that synergy values (R) were quantified using the ratio of IC50 
of each primary drug alone (5-fluorouracil, oxaliplatin, and 
irinotecan) divided by combination IC50
DISCUSSION 
s. NaPB showed a 
statistically significant synergistic effect against the two cell lines 
when combined with 5-fluorouracil, oxaliplatin, and irinotecan, as 
indicated by (R) values (p-value<0.05) (table 2).  
Conventional chemotherapy containing 5-fluorouracil, oxaliplatin, 
and irinotecan remain the major anticancer therapy for colorectal 
cancer, but the resistance to these agents has negatively affected the 
overall survival of patients. Resistance to anticancer therapy can 
occur through different mechanisms such as impaired permeability, 
DNA mutations, metabolic changes, DNA damage repair, epigenetic 
alterations, and others [15]. Epigenetic mechanisms are critical for 
the normal genetic development of the mammalian cells, and cancer 
is believed to develop due to the accumulation of genetic and 
epigenetic aberrations through a multistep process [14-23], creating 
a heterogeneous disease at both cellular and molecular levels [24].  
Thus, epigenetic aberrations play a significant role in cancer 
development and progression and anticancer therapy resistance 
[15]. There is a high continued interest toward the inclusion of 
relatively safe drugs such as HDACIs in the conventional 
chemotherapy and there are several lines of evidence that support 
the effectiveness of HDACIs in enhancing the antineoplastic activity 
of anticancer agents in colorectal cancer. CG2 (a HDACI) enhanced 
the cytotoxicity of 5-fluorouracil, oxaliplatin, and irinotecan against 
HCT-116 colorectal cancer cell lines [25]. Furthermore, PXD101 (a 
HDACI) plus 5-fluorouracil or irinotecan combination showed a 
synergistic effect in colorectal cancer in vitro and in vivo [26, 27]. 
MS275 or SBHA (HDACIs) combined with oxaliplatin showed high 
synergistic activity against colorectal cancer cells [28]. 
The current study was performed in an attempt to identify the 
synergistic potential of the HDACI NaPB when combined with 5-
fluorouracil, oxaliplatin, or irinotecan in colorectal cancer. Initially, 
we found that NaPB inhibited the growth of HCT-116 and HT-29 cell 
lines in a dose-dependent manner. Although statistically not 
significant, HCT-116 showed to be more sensitive to NaPB than HT-
29 with about two-fold difference in IC 50
We also demonstrated that at low and clinically achievable 
concentrations, NaPB synergistically inhibited colorectal cancer cell 
proliferation in HCT-116 and HT-29 cell lines when combined with 
5-fluorouracil, oxaliplatin, and irinotecan in a concentration-
dependent manner. This synergistic effect can be explained by 
s. On the other hand, at 
concentrations below 4 mmol, the HT-29 cell line was more 
sensitive to NaPB than HCT-116 (p<0.05). The difference in 
response to NaPB may indicate that the anticancer effect of this 
agent is dependent on the p53 status; HCT-116 cell lines express p53 
in wild-type conformation, while HT-29 harbor mutant p53; there is 
a G to A mutation in codon 273 of the gene that results in an arginine 
to histidine substitution (R273H). This missense mutation is 
associated with loss of wild-type activity and overexpression of a 
mutant p53 with oncogenic functions “gain of functions” phenotypes 
[29]. p53, is a tumor suppressor protein that works intracellularly to 
promote apoptosis or autophagy of the tumor cells [30-31], and it is 
the most commonly mutated gene in cancer with a mutation rate of 
about 50% in colorectal cancer [32, 33]. There is controversy 
regarding the effect of p53 status on the sensitivity of tumors to 
anticancer therapy. Some studies revealed that p53 overexpression, 
a surrogate marker of p53 mutation, is associated with increased 
resistance to 5-fluorouracil, oxaliplatin, and irinotecan [7, 34]; 
cancer cell lines with a mutation in the p53 gene were more prone to 
resistance than wild-type cell lines [7, 34]. While others revealed 
that p53-mutant cells are more sensitive to anticancer therapy [35-
36]. Our findings reveal higher sensitivity to NaPB in p53 mutant 
cancer cell line (HT-29) than p53 wild-type cancer cell line (HCT-
116). Thus, further investigations are required to identify the 
mechanism of the mutant-type p53-dependent antiproliferative 
effect of NaPB. 
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several mechanisms; NaPB inhibits class I HDAC enzymes, resulting 
in the reprogramming of gene expression and posttranslational 
modifications [19]. As a consequence, NaPB therapy is associated 
with inhibition of cellular proliferation, metastasis, and 
angiogenesis, and induction of cell cycle arrest and apoptosis. It is 
worth to note that NaPB was able to enhance the cytotoxicity of the 
tested drugs against the p53 mutant cell line (HT-29); NaPB may 
have activated the transcriptional activity of p53 in HT-29 cell line, 
which as a consequence resulted in enhanced apoptosis induced by 
5-fluorouracil, oxaliplatin, and irinotecan. Our findings are 
consistent with the goal of several studies that focus on identifying 
approaches to target p53 either by activating it in p53-deficient 
cancer cells, or changing the conformation of mutant p53 to wild-
type form (reactivation) to enhance the antitumor effects of 
anticancer therapy [36, 37]. Our results suggest that NaPB is a 
potential adjuvant anticancer agent with a beneficial role in 
overcoming resistance to 5-fluorouracil, oxaliplatin, and irinotecan. 
Further in vivo and clinical studies are required to study the effect of 
combinational therapies containing NaPB in colorectal cancer, 
especially those expressing the mutant p53. 
CONCLUSION 
In conclusion, this study shows that NaPB has synergistic anticancer 
effect with 5-fluorouracil, oxaliplatin, and irinotecan against 
colorectal cancer. Future work will more fully investigate the 
underlying molecular mechanisms of synergism and the p53-
dependent anti-proliferative activity. 
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